Repatha Alternatives: 6 Options Compared by LDL Drop and Cost

What are the alternatives to Repatha, and why do people switch?

The main Repatha alternatives are Praluent, Leqvio, Lipfendra, Lerochol, bempedoic acid and ezetimibe, and the right one depends on why Repatha isn't working for you. Most people look for an alternative because of cost or coverage, needles, side effects, or because they need less lowering of LDL cholesterol (LDL-C) than Repatha provides.

Repatha (evolocumab) is a well-studied cholesterol medicine. It lowers LDL by about 60% and has outcomes trials showing fewer heart attacks and strokes. Still, some people need something else, usually for one of these reasons:

• Cost or coverage. Their plan prefers a different drug, or the out-of-pocket cost is too high. (Our Repatha cost guide covers ways to lower it.)
• Needles. Some people would rather not inject themselves every two to four weeks.
• Side effects. Injection-site reactions or other symptoms on Repatha.
• Less LDL lowering needed. Sometimes a smaller step closes the gap.

Here's what's available as of October 2026.

Enter your LDL and goal to see what each medicine could do on average.

What drug is most similar to Repatha? Praluent (alirocumab)

Praluent is the closest alternative to Repatha: the same kind of medicine, similar LDL lowering, and its own outcomes trial. Like Repatha, Praluent works as an antibody that blocks PCSK9, a liver protein that breaks down LDL receptors (the parts of liver cells that pull LDL out of your blood). It's a self-injection every 2 weeks, or a higher dose every 4 weeks (Sanofi prescribing information).

Praluent has its own outcomes trial. In ODYSSEY OUTCOMES, nearly 19,000 people who had recently had a heart attack or unstable angina took Praluent or placebo on top of a statin. Praluent lowered the risk of major cardiovascular events by 15%.

Because Repatha and Praluent are so similar, insurers often cover one and not the other. If your plan prefers Praluent, switching is usually simple.

Is there a Repatha alternative with fewer shots? Leqvio (inclisiran)

Leqvio is an siRNA, a medicine that tells the liver to make less PCSK9 rather than blocking PCSK9 after it's made. A healthcare professional gives it as a shot: once, again at 3 months, then every 6 months. In its main trials it lowered LDL by about 50%. Its outcomes trials (ORION-4 and VICTORION-2 PREVENT) have not reported results as of October 2026. Full details are in our Leqvio guide.

Is there a pill like Repatha? Lipfendra (enlicitide)

Lipfendra, made by Merck, was approved by the FDA in July 2026 as the first oral PCSK9 inhibitor. It's a once-daily tablet. In the phase 3 CORALreef trials it lowered LDL by 56% and 59% compared with placebo at 24 weeks (Merck).

It launched at a list price of $315 a month. Its cardiovascular outcomes trial is still underway. See our Lipfendra guide for the dosing rules (it has to be taken on an empty stomach with a wait before eating).

Is there a monthly alternative to Repatha? Lerochol (lerodalcibep)

Lerochol, from LIB Therapeutics, was approved by the FDA in December 2025 and launched in the US in May 2026. It's a once-monthly self-injection that can stay at room temperature for up to three months, which makes travel easier. In its pivotal trial it lowered LDL by about 56% compared with placebo over a year (TCTMD). LIB Therapeutics offers a direct-to-patient cash price of $199 a month (LIB Therapeutics). No outcomes trial has reported yet. An autoinjector pen was approved in August 2026 and is expected by January 2027 (LIB Therapeutics). More in our Lerochol guide.

How does bempedoic acid (Nexletol) compare with Repatha?

Bempedoic acid lowers LDL by about 20%, compared with about 60% for Repatha, but it is a non-statin pill with its own outcomes data. Bempedoic acid works in the same cholesterol-making pathway as statins, one step earlier, but the liver activates it and muscle largely lacks the enzyme to do so. It's a daily pill, also available combined with ezetimibe (Nexlizet).

In CLEAR Outcomes, about 14,000 people who couldn't take statins took bempedoic acid or placebo. LDL dropped about 21% more than with placebo, and major cardiovascular events fell by 13%.

It lowers LDL far less than a PCSK9 inhibitor, so it fits best when you're relatively close to your goal. The 2026 ACC/AHA multisociety guideline elevated bempedoic acid to a first-line non-statin option (ACC).

Is there a cheaper alternative to Repatha? Ezetimibe and others

Ezetimibe is usually the least expensive option. Among the PCSK9 options, Lerochol has a direct-to-patient cash price of $199 a month. Ezetimibe blocks cholesterol absorption in the gut. It's a generic daily pill, usually inexpensive, and typically lowers LDL by roughly 20 to 25% when added to a statin. In IMPROVE-IT, adding ezetimibe to a statin after a heart attack or unstable angina modestly lowered cardiovascular events over about six years.

This chart compares a year of cash or list prices.

Getting more from a statin

Sometimes a better-fitting statin is the best alternative. Before moving on, ask whether your statin is doing all it can. A higher-intensity statin, a different statin, or a different schedule can make a real difference, and many people who had side effects on one statin do fine on another. Our guide to statin side effects goes through how to tell what's causing symptoms.

Side-by-side comparison

LDL-C numbers come from each drug's main trials, compared with placebo, and different trials enrolled different people, so use them as ballpark figures for rough comparison.

Which Repatha alternatives may be easier to tolerate?

No trial has compared these medicines head to head for side effects, so none of them can be called easier to tolerate. Each label states that adverse reaction rates from different trials can't be compared directly. The labels do list what people taking each medicine reported in its own trials, and those lists help you decide what to ask your clinician about.

• Repatha. In a 52-week trial, injection-site reactions occurred in 5.7% of people on Repatha and 5.0% on placebo. Stopping because of side effects happened in 2.2% versus 1% (Repatha prescribing information).
• Praluent. Injection-site reactions occurred in 7.2% on Praluent and 5.1% on placebo, and 5.3% versus 5.1% stopped treatment because of side effects (Sanofi prescribing information).
• Leqvio. Injection-site reactions occurred in 8% on Leqvio and 2% on placebo, mostly pain, redness, or rash. Joint pain (5% versus 4%) and bronchitis (4% versus 3%) were the other common reactions (Leqvio prescribing information).
• Lerochol. Injection-site reactions occurred in 12% on Lerochol and 5% on placebo in two pooled 52-week trials, and stopping because of side effects occurred in 4% of both groups (FDA label, revised August 2026).
• Lipfendra. Side effects in the larger trial looked similar to placebo. In a smaller trial of people with familial hypercholesterolemia, diarrhea occurred in 7% versus 2% and dizziness in 9% versus 4% (Merck prescribing information).
• Bempedoic acid (Nexletol). The label lists higher uric acid, gout, and tendon rupture. Tendon rupture occurred in 0.5% versus 0% in the cholesterol trials, so people with prior tendon problems or who take certain antibiotics or steroids should ask their clinician first (Nexletol prescribing information).
• Ezetimibe. Alone, the most common reactions were upper respiratory infection (4.3% versus 2.5% on placebo) and diarrhea (4.1% versus 3.7%), in a 12-week median exposure (Zetia prescribing information).

If injection-site reactions bother you, the pills avoid them. The label figures above come from different trials with different people, so use them as a list of things to ask about.

Which Repatha alternatives should I compare before asking my doctor?

Start with how far your LDL or ApoB is from goal, then weigh evidence, how you want to take it, and how you'll pay. Four steps sort this out before your visit.

For the bigger picture on the PCSK9 class, see PCSK9 inhibitors explained.

How Preval Health helps

Preval Health focuses only on prescription cholesterol care. Our treatment protocols are written by a board-certified preventive cardiologist, and licensed clinicians prescribe through our partner telehealth network.

We help you pick the option that fits your numbers and your life, then get it. Preval runs as a cash practice: partner clinicians prescribe, and we help you use manufacturer direct programs. Care costs $99 a month, and you pay the medicine's cash price. We recheck your labs every quarter, and your clinician adjusts from there. See how to get a PCSK9 inhibitor prescription online for what the process looks like.